Fig. 2: Baseline characteristics for IDH2 mutated AML patients and the association with clinical outcomes after allogeneic hematopoietic cell transplant.
From: Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Cumulative incidence of relapse (left) and overall survival (right) are shown for IDH2 mutated patients by the presence (IDH2 NGS MRDpos) or absence (IDH2 NGS MRDneg) of residual IDH2 variants and by (a) age group below 60 years old, (b) age group 60 years or above, (c) different variant allele fraction (VAF) groups, and (d) by IDH2 mutation type.
